Scinai Immunotherapeutics Secures $10M Equity Line
Ticker: SCNI · Form: 6-K · Filed: Mar 4, 2025 · CIK: 1611747
| Field | Detail |
|---|---|
| Company | Scinai Immunotherapeutics Ltd. (SCNI) |
| Form Type | 6-K |
| Filed Date | Mar 4, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: equity-financing, capital-raise
TL;DR
Scinai just inked a $10M equity line with Yorkville for up to 36 months.
AI Summary
On March 3, 2025, Scinai Immunotherapeutics Ltd. entered into a Standby Equity Purchase Agreement with YA II PN, LTD. This agreement allows Scinai to sell up to $10 million of its ordinary shares to Yorkville over a 36-month period, subject to certain conditions.
Why It Matters
This equity line provides Scinai with flexible access to capital, which can be crucial for funding ongoing research and development or potential future acquisitions.
Risk Assessment
Risk Level: medium — Standby equity agreements can dilute existing shareholders and may indicate the company needs capital for operational needs.
Key Numbers
- $10.0M — Equity Line (Maximum amount Scinai can draw down from Yorkville over 36 months.)
Key Players & Entities
- Scinai Immunotherapeutics Ltd. (company) — the registrant
- YA II PN, LTD. (company) — purchaser in the equity agreement
- $10 million (dollar_amount) — maximum amount available under the equity purchase agreement
- 36-month period (date) — duration of the equity purchase agreement
- March 3, 2025 (date) — date the agreement was entered into
FAQ
What is the primary purpose of the Standby Equity Purchase Agreement?
The agreement allows Scinai Immunotherapeutics Ltd. to sell up to $10 million of its ordinary shares to YA II PN, LTD. over a 36-month period, providing flexible access to capital.
Who is the counterparty to Scinai in this equity agreement?
The counterparty is YA II PN, LTD., a Cayman Islands exempt limited partnership, referred to as 'Yorkville'.
What is the maximum amount Scinai can raise through this agreement?
Scinai can raise up to $10 million through the sale of its ordinary shares under the terms of the agreement.
Over what period can Scinai utilize this equity line?
The agreement is effective for a period of 36 months from the date it was entered into.
What is the filing date of this Form 6-K?
This Form 6-K was filed on March 4, 2025.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 4, 2025 regarding Scinai Immunotherapeutics Ltd. (SCNI).